Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

134.80 +1.45 (+1.09%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
44 45 Next >
Abbott Recalls Amplatzer Steerable Delivery Sheath On Risk Of Air Embolism
Abbott Laboratories (NYSE: ABT) is recalling the Amplatzer Steerable Delivery Sheath due to an increased  
Via Benzinga
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
2 Top Dividend Stocks to Buy and Hold Forever
They have been paying dividends for a long time. 
Via The Motley Fool
Russia Is Seizing European Company Assets — What US Businesses Are Still At Risk?
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript
ABT earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Abbott Stock Edges Higher As Earnings Decline But Still Top Forecasts
The company continues to expect some Covid sales this year, but cut its outlook. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Ultrareliable Dividend Stocks to Buy and Hold for Decades
These stocks have decades of annual dividend raises under their belts, and rising healthcare costs mean there could be plenty more to come. 
Via The Motley Fool
Apple To Rally Over 17%? Here Are 10 Other Analyst Forecasts For Monday
Citigroup raised the price target for Cintas Corporation (NASDAQ: CTAS) from $540 to $550. Citigroup analyst Leo Carrington downgraded the stock from Buy to Neutral. Cintas shares fell 0.8% to $503.43... 
Via Benzinga
Abbott's Higher Than Expected Q2 Earnings: Analyst Foresees Strong Performance In 2024
Thursday, Abbott Laboratories (NYSE: ABT) reported better-than-expected Q2 earnings. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
J&J, Abbott Labs And JPM Among Jim Cramer's Top Picks As Market Shifts Focus From Tech
Via Benzinga
Johnson & Johnson's Inflection Point: What it Means for Investors
Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories Has the Prescription for Higher Share Prices
Abbott Laboratories stock is ready to rebound after a year of correction. The decline of COVID is priced into the market, and organic growth is accelerating. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories's Earnings Outlook
Via Benzinga
What's In Store For Abbott Laboratories In Q2 Earnings?
Abbott Laboratories is slated to report second-quarter 2023 results on July 20 before the market opens. 
Via Talk Markets
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Tesla Recalls Over 17K EVs Over Camera & Seat Belt Issues, University Research Uncovers Unexpected Fluctuations In ChatGPT Capabilities, Juul Seeks FDA Nod For Next-Generation Vaporizer: Today's Top Stories
Benzinga Tesla Recalls More Than 17,000 EVs Over Camera, Seat Belt Issues 
Via Benzinga
Abbott Laboratories Clocks Strong Q2 Growth In Underlying Base Business, Reaffirms FY23 Outlook
Abbott Laboratories (NYSE: ABT) has reported Q2 FY23 adjusted EPS of $1.08, down 25% Y/Y, beating the consensus of $1.05. 
Via Benzinga
Johnson & Johnson, Tesla And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Markets Remain Bullish After Dow Rises For Eighth Consecutive Session
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Wednesday. The Dow Jones gained recorded gains for the eighth straight session on Wednesday, its longest winning streak since... 
Via Benzinga
(ABT) - Analyzing Abbott Laboratories's Short Interest
Via Benzinga
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Earnings Scheduled For July 20, 2023
Companies Reporting Before The Bell • Taiwan Semiconductor (NYSE:TSM) is estimated to report quarterly earnings at $1.08 per share on revenue of $15.49 billion. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Abbott Scores FDA Nod For First Dual-Chamber Leadless Pacemaker To Treat Abnormal, Slow Heart Rhythms
The FDA has approved Abbott Laboratories' (NYSE: ABT) AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system to treat  
Via Benzinga
GE HealthCare's Solid Demand And Sensible Margin Targets: Morgan Stanley Sees Potential Upside Despite Street's High Expectations
Morgan Stanley analyst Patrick Wood initiated coverage on GE HealthCare Technologies Inc (NASDAQ: GEHC) with an Equal-Weight rating and a  
Via Benzinga
Dexcom, A Top 2% Stock, Raises 2025 Outlook Amid 'Rapidly' Expanding Diabetes Market
The company makes continuous glucose monitors for patients with diabetes. 
Via Investor's Business Daily
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback